Bone Reports (Jun 2020)

Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis

  • Eleonora Palagano,
  • Sharon Muggeo,
  • Laura Crisafulli,
  • Irina L. Tourkova,
  • Dario Strina,
  • Stefano Mantero,
  • Elena Fontana,
  • Silvia L. Locatelli,
  • Marta Monari,
  • Emanuela Morenghi,
  • Carmelo Carlo-Stella,
  • John B. Barnett,
  • Harry C. Blair,
  • Paolo Vezzoni,
  • Anna Villa,
  • Cristina Sobacchi,
  • Francesca Ficara

Journal volume & issue
Vol. 12
p. 100242

Abstract

Read online

Background: Autosomal recessive osteopetrosis is a rare skeletal disorder with increased bone density due to a failure in osteoclast bone resorption. In most cases, the defect is cell-autonomous, and >50% of patients bear mutations in the TCIRG1 gene, encoding for a subunit of the vacuolar proton pump essential for osteoclast resorptive activity. The only cure is hematopoietic stem cell transplantation, which corrects the bone pathology by allowing the formation of donor-derived functional osteoclasts. Therapeutic approaches using patient-derived cells corrected ex vivo through viral transduction or gene editing can be considered, but to date functional rescue cannot be demonstrated in vivo because a relevant animal model for xenotransplant is missing. Methods: We generated a new mouse model, which we named NSG oc/oc, presenting severe autosomal recessive osteopetrosis owing to the Tcirg1oc mutation, and profound immunodeficiency caused by the NSG background. We performed neonatal murine bone marrow transplantation and xenotransplantation with human CD34+ cells. Results: We demonstrated that neonatal murine bone marrow transplantation rescued NSG oc/oc mice, in line with previous findings in the oc/oc parental strain and with evidence from clinical practice in humans. Importantly, we also demonstrated human cell chimerism in the bone marrow of NSG oc/oc mice transplanted with human CD34+ cells. The severity and rapid progression of the disease in the mouse model prevented amelioration of the bone pathology; nevertheless, we cannot completely exclude that minor early modifications of the bone tissue might have occurred. Conclusion: Our work paves the way to generating an improved xenograft model for in vivo evaluation of functional rescue of patient-derived corrected cells. Further refinement of the newly generated mouse model will allow capitalizing on it for an optimized exploitation in the path to novel cell therapies.

Keywords